{"schema_version":"1.0","type":"article","title":"GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.md","lang":"zh-Hant","date":"2026-06-17","publish_at":"2026-06-17T09:30:00+08:00","updated_at":"2026-06-17","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","肥胖藥","Ecnoglutide","Wegovy","輝瑞","諾和諾德","臨床數據","生技投資"],"summary":"ADA 2026 剛落幕，GLP-1 賽道又被一組頭對頭資料點燃。Ecnoglutide 在 20 週減重數字上勝出，但真正的競爭不只看短期體重下降，而是長期健康結局、耐受性、產品矩陣與全球商業化。","key_points":[],"facts":[],"sections":["01｜這場「頭對頭」有亮點，但也有邊界","02｜「減得更多」不等於「藥更好」","03｜Wegovy 的護城河，不只是 semaglutide 這個分子","04｜Ecnoglutide 的破局點：偏向性 GLP-1 設計，能不能換來耐受性與療效平衡？","05｜Novo Nordisk 也沒有坐著等：7.2 mg semaglutide 已經補上更高劑量","06｜Pfizer 的機會與壓力：中國市場是入口，但全球競爭更難","07｜GLP-1 的決勝時間，不在今天，而在 2027 到 2028 年","08｜台灣重點仍是康霈與奧孟亞這兩條外溢路線","結語｜GLP-1 巨頭之戰，不是誰短期減更多，而是誰能回答「減重之後」的問題"],"references":[{"title":"[1] Novo Nordisk","source":"Wegovy U.S. prescribing information:","date":"","url":"https://www.novo-pi.com/wegovy.pdf"},{"title":"[2] Pfizer","source":"Obesity and metabolic disease pipeline:","date":"","url":"https://www.pfizer.com/science/drug-product-pipeline"},{"title":"[3] Sciwind Biosciences","source":"Ecnoglutide / GLP-1 pipeline and company information:","date":"","url":"https://www.sciwind.com/"},{"title":"[4] U.S. FDA","source":"Drug approvals and databases:","date":"","url":"https://www.fda.gov/drugs"},{"title":"[5] World Health Organization","source":"Essential medicines and health-product updates:","date":"","url":"https://www.who.int/teams/health-product-policy-and-standards/essential-medicines"}],"images":[{"alt":"Facebook 原圖：Ecnoglutide 與 Wegovy 頭對頭減重資料整理","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-01.jpg"},{"alt":"Facebook 原圖：藥時事與 CMoney 減肥藥賽道投資課程","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-02.jpg"},{"alt":"Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-03.jpg"},{"alt":"Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-04.jpg"},{"alt":"Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-05.jpg"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-17）。GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？。https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}